Radnet Stock Price, News & Analysis

RadNet (NASDAQ:RDNT) has completed the acquisition of iCAD (NASDAQ:ICAD), a global leader in AI-powered breast health solutions, through its wholly-owned subsidiary DeepHealth. The strategic acquisition integrates iCAD's extensive AI portfolio for breast cancer detection with DeepHealth's screening solutions, expanding their reach to over 10 million mammograms annually.

iCAD's technology portfolio, deployed in more than 50 countries across 1,500+ healthcare provider locations, includes solutions for breast cancer detection, risk evaluation, breast density, and arterial calcification assessment. The combination aims to enhance AI model performance and accelerate the adoption of advanced breast cancer screening technologies worldwide, particularly in underserved communities.

RadNet (NASDAQ:RDNT), a leading outpatient diagnostic imaging services provider, announced that Regal Medical Group, Lakeside Community Healthcare, and ADOC Medical Group will include RadNet's Enhanced Breast Cancer Detection (EBCD) program in their members' health plans.

These medical groups, serving nearly 600,000 members across Southern California, will provide AI-powered breast cancer detection services to all mammogram-eligible patients. RadNet will implement a patient outreach program to boost compliance with annual screening guidelines. The program represents significant progress in securing EBCD reimbursement from commercial payors.

The collaboration aims to improve early breast cancer detection, as one in eight women will develop breast cancer in their lifetime. The AI-powered EBCD program can detect breast cancer earlier than traditional methods, potentially improving patient outcomes through earlier intervention.

RadNet (NASDAQ: RDNT) has acquired See-Mode Technologies, an AI innovator in ultrasound imaging diagnostics. See-Mode's FDA-approved AI solutions for thyroid and breast ultrasound detection will be integrated into RadNet's DeepHealth population health solutions. The acquisition demonstrates significant operational benefits, with early deployment showing up to 30% reduction in scan time across RadNet's imaging centers. RadNet performs approximately 250,000 annual thyroid ultrasounds and over two million total ultrasound studies yearly across 900+ units. The integration aims to improve diagnostic accuracy, enhance workflow efficiency, and generate standardized reports. The acquisition strengthens RadNet's position in AI-powered healthcare solutions, particularly in addressing thyroid and breast cancer diagnostics, which represent approximately 20 million ultrasound exams annually in the US alone.

RadNet (RDNT) reported Q1 2025 financial results with total revenue increasing 9.2% to $471.4 million despite weather-related challenges. The company's Digital Health segment saw strong growth with revenue up 31.1% to $19.2 million. However, Adjusted EBITDA decreased 20.6% to $46.4 million, primarily due to a $15 million impact from Southern California wildfires and severe winter weather. The company reported an Adjusted Loss Per Share of $(0.35) compared to earnings of $0.07 in Q1 2024. Notably, RadNet announced plans to acquire iCAD to enhance AI-powered breast cancer detection capabilities. Based on strong business recovery and positive trends, RadNet revised its 2025 guidance upward, with revenue now expected between $1.835-$1.885 billion and Adjusted EBITDA between $268-$276 million.

RadNet (NASDAQ: RDNT), a leading national provider of diagnostic imaging services, announced that Executive Vice President and CFO Mark Stolper will present at the Bank of America Securities 2025 Healthcare Conference. The presentation is scheduled for May 13, 2025, at 5:00 p.m. Pacific Time at the Encore Hotel in Las Vegas, NV.

RadNet operates 398 outpatient imaging centers across eight states including Arizona, California, Delaware, Florida, Maryland, New Jersey, New York, and Texas. The company provides diagnostic imaging services, radiology information technology, AI solutions through DeepHealth, and teleradiology services. RadNet employs over 11,000 people, including contracted radiologists, full-time and per diem employees, and technologists.

GE HealthCare (GEHC) will showcase its latest breast health technology advancements at the 2025 Society of Breast Imaging Symposium in Colorado Springs. The company is featuring several key innovations:

The Pristina Via™ mammography system offers streamlined workflows with zero-click acquisition, no wait time between exposures, and faster DBT image-to-image cycle times. The company will distribute DeepHealth's SmartMammo™, an AI-powered solution for breast cancer screening, now commercially available in the U.S.

Additional innovations include the Invenia™ ABUS Premium, the first FDA-approved breast ultrasound for dense breast detection, showing a 35.7% increase in cancer detection when used with mammography. The company also presents SenoBright™ HD and SerenaBright™, the first FDA-cleared Contrast Enhanced Mammography and CEM biopsy solutions.

RadNet Inc (NASDAQ: RDNT), a national leader in providing diagnostic imaging services through owned and operated outpatient centers, has scheduled its first quarter 2025 financial results conference call for Monday, May 12, 2025 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time).

Investors can participate by dialing 844-826-3035 (US) or 412-317-5195 (International). The event will feature simultaneous and archived webcasts accessible at the provided ViaVid link. A replay will be available by calling 844-512-2921 (US) or 412-317-6671 (International) using passcode 10199390.

RadNet (NASDAQ: RDNT) has announced the acquisition of iCAD (NASDAQ: ICAD) in an all-stock transaction valued at approximately $103 million. Under the agreement, iCAD stockholders will receive 0.0677 shares of RadNet common stock for each iCAD share, representing $3.61 per share and a 98% premium based on April 14, 2025 closing prices.

The merger combines iCAD's ProFound Breast Health Suite with RadNet's DeepHealth AI-powered breast screening solutions. iCAD's network spans over 1,500 healthcare provider locations across 50 countries, facilitating over 8 million annual mammograms. The integration aims to enhance breast cancer detection accuracy and early diagnosis capabilities.

The transaction, unanimously approved by both companies' boards, is expected to close in Q2 or Q3 2025, subject to iCAD stockholder approval and customary closing conditions.

RadNet (NASDAQ: RDNT), a national leader in diagnostic imaging services, has announced its participation in the upcoming 35th Annual Oppenheimer Healthcare MedTech & Services Conference. The company's Executive Vice President and Chief Executive Officer, Mark Stolper, will deliver a virtual presentation on March 17, 2025, at 12:40 p.m. Eastern Time.

The presentation will be accessible through a live webcast at wsw.com/webcast/oppenheimer40/rdnt/2795776, with replay options available. RadNet operates a network of fully-owned and operated outpatient imaging centers, focusing on providing high-quality, cost-effective diagnostic imaging services.